Baclofen Deal Offers Amneal Biosimilars Advantage
Firm Accelerates Biosimilars Schedule, With Three Launches Now Planned For This Year
Amneal says an $83.5m deal to acquire Saol Therapeutics’ baclofen franchise will also bring the firm an “experienced institutional commercial team” that will be able to support three biosimilar launches that the company now expects to execute in 2022.
